Fermenta Biotech
320.15
+19.60(+6.52%)
Market Cap₹942.18 Cr
PE Ratio7.98
IndustryHealthcare
Company Performance:
1D+6.52%
1M+19.68%
6M-4.46%
1Y-21.91%
5Y-7.26%
View Company Insightsright
More news about Fermenta Biotech
23Sept 25
Fermenta Biotech Limited Earns Great Place to Work Certification for 2025-2026
Fermenta Biotech Limited, a manufacturer of APIs, intermediates, and nutritional premixes, has been certified as a Great Place to Work for 2025-2026. The certification is based on confidential employee feedback, focusing on workplace culture, engagement, and trust. Fermenta serves over 400 customers in more than 60 countries and operates manufacturing facilities in Kullu, Dahej, and Tirupati, with an R&D Excellence Centre in Thane. The company emphasizes nurturing leadership, employee well-being, and fostering a culture of growth and inclusivity.
19Sept 25
Fermenta Biotech to Divest Environment Business for Rs 19 Crores in Strategic Move
Fermenta Biotech Limited (FBL) has approved the sale of its environmental solutions business to its wholly-owned subsidiary, Fermenta Environment Solutions Private Limited (FESPL), for Rs 19 crores. The transaction, structured as a slump sale, is set to be effective from October 1, 2025, with completion expected within 60 days. The environmental solutions business contributed Rs 22.20 crores (5.02%) to FBL's total revenue last year and has a net worth of Rs 15.53 crores. This move aims to enhance operational efficiency, enable specialized management, and accelerate growth in the environmental sector. FESPL will continue to provide various environmental solutions including waste management, water treatment, and pollution control.
12Sept 25
Fermenta Biotech Secures Patent for Innovative Plant-Based Vitamin D3 Process
Fermenta Biotech Limited has been granted a patent by the Indian Patent Office for its proprietary plant-based Vitamin D3 manufacturing process. This innovation enables the production of vegan and vegetarian-friendly Vitamin D3, addressing the growing demand for sustainable nutrition solutions. The company, serving over 400 customers across 60 countries, is well-positioned to capitalize on the increasing trend towards plant-based nutritional ingredients. Prashant Nagre, Managing Director, emphasized the significance of this development for both the company and India's role in industrial innovation.
12Aug 25
Fermenta Biotech Reports Strong Q1 EBITDA Growth to 282M Rupees
Fermenta Biotech Limited announced approval of its Q1 unaudited financial results. The company's EBITDA reached 282.00 million rupees, up from 8.00 million rupees in the same period last year. EBITDA margin improved to 20.70% from 1.03%. The board meeting was held on August 12, reviewing both standalone and consolidated operations for the quarter ended June 30. Limited Review Reports were submitted by statutory auditors SRBC & Co. LLP.
29Jul 25
Fermenta Biotech Secures European Certification for Vitamin D3 Product, Boosting Global Market Position
Fermenta Biotech Limited has received a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & Healthcare (EDQM) for its VITADEETM 100 SD product, a spray-dried variant of Vitamin D3. The certification applies to the product manufactured at the company's Kullu, Himachal Pradesh facility. This achievement makes Fermenta one of only two companies globally to hold a CEP for this Vitamin D3 variant, reinforcing its commitment to regulatory compliance and quality standards. The certification is expected to enhance Fermenta's position in the international health and nutrition industry and expand its global presence.
29May 25
Fermenta Biotech Swings to Profit in Q4, Announces Dividend
Fermenta Biotech Ltd, a leading Vitamin D3 manufacturer, has reported a significant financial turnaround in Q4. The company posted a consolidated net profit of ₹343.90 crore, compared to a loss of ₹69.00 crore in the same period last year. Revenue increased by 44% to ₹1,400.00 crore. The board has recommended a final dividend of ₹2.50 per equity share.
28May 25
Fermenta Biotech Reports Strong Q4 Results, Declares Dividend
Fermenta Biotech Ltd. announced impressive Q4 financial results, with revenue reaching ₹1.40 billion, up 43.89% year-over-year. The company's profitability surged, with EBITDA increasing to ₹369.40 million and net profit turning positive at ₹343.90 million, compared to a loss in the previous year. The board recommended a final dividend of ₹2.50 per equity share.
Fermenta Biotech
320.15
+19.60
(+6.52%)
1 Year Returns:-21.91%
Industry Peers
Sun Pharmaceutical
1,807.20
(+1.22%)
Divis Laboratories
6,430.00
(+2.15%)
Torrent Pharmaceuticals
3,799.00
(+0.12%)
Cipla
1,512.30
(+1.44%)
Dr Reddys Laboratories
1,273.50
(+1.81%)
Lupin
2,081.80
(+1.28%)
Zydus Life Science
922.55
(-0.11%)
Mankind Pharma
2,166.80
(+0.83%)
Aurobindo Pharma
1,172.20
(-0.03%)
Alkem Laboratories
5,626.00
(+0.49%)